Chairman of the Board
Chairman of the Board
We pledge to continue Samsung’s legacy of excellence
by combining our business to bring innovation and progress to
today’s biopharmaceutical industry.
Chairman's Experience Detail
- Education
- Dr. Kim holds a doctoral degree in chemical engineering from the University of Texas at Austin.
- Experience
-
Dr. Kim also served in Samsung Group's Strategic Planning Office and held a senior leadership position for Samsung
Total Petrochemicals, a Joint Venture Company between Total of France and Samsung.
Dr. Kim began his career with Samsung in 1979. Dr. Kim led the business and financial restructuring of Samsung General Chemicals from 1997 to 2003. After establishing a joint venture, Dr. Kim developed and executed multiple expansion projects, including the creation of a naphtha cracking center, an aromatics plant, and polypropylene and styrene monomer production plants.
Chairman's Message Detail
Samsung Biologics entered the biopharmaceutical industry during a time of significant changes.
The global availability and capacity for biologics manufacturing are decreasing, and new innovative types of medicines are being developed to help millions
suffering from devastating diseases.
Our vision is to become the most competitive CDMO and offer a significant increase in available capacity, quality, and innovation. This will allow our client partners to provide valuable biological medicines to their patients both cost-effectively and on time. To realize this vision, we have built a unique continual processing platform for the manufacturing of biopharmaceutical products with quality and executional excellence in compliance with global regulatory bodies including the FDA, EMA, PMDA, and MFDS.
We pride ourselves in delivering superior customer satisfaction through better quality, superior service, and compliance. Based on Samsung’s principles of Quality First and a track record for excellence in plant design, construction, operations, and execution, our competitiveness surpasses that of our rivals without sacrificing quality, regulatory compliance, or our business ethics. While continuing to implement current industry best practices, we strive together with our clients to set higher standards for biopharmaceutical manufacturing.
Our operations are designed to fully comply with international regulatory and CGMP requirements and are overseen by our Quality Division. Our advanced facilities
are able to manufacture biological products from early development through commercial supply stages. Furthermore, our experienced people provide expertise
in cell line development, culture, purification, analytical testing, aseptic filling, and packaging.
Our diverse capabilities, manufacturing scale, and flexibility represent a truly integrated one-stop service that meets all our clients’ needs.
We will continue expanding our facilities and capabilities to meet growing market demand. As a global company, we pledge to continue Samsung’s legacy of excellence by combining our business, manufacturing, and engineering expertise, to bring innovation and progress to today’s biopharmaceutical industry.